skip to main content
Give

Lixian Zhong

Lixian Zhong
Lixian Zhong, PhD

Associate Professor of Pharmaceutical Sciences

Contact

Texas A&M Irma Lerma Rangel School of Pharmacy
Mail Stop 1114 159 Reynolds Medical Building
College Station, TX 77843-1114
zhong@tamu.edu
Phone: 979.436.0193
Fax: 979.436.0087

Education and Training

  • University of California, San Francisco, Post-doctoral Fellow in Pharmacoeconomics and Outcomes Research, 2011-2013
  • Duke University, Durham, North Carolina, PhD in Pharmacology, 2011
  • Duke University, Durham, North Carolina, Master of Arts in Economics, 2010
  • Peking University, Beijing, P.R. China, Bachelor of Science in Biological Sciences, 2003

Research Interests

  • Pharmacoeconomic modeling
  • Healthcare cost and resource utilization
  • Drug pricing and reimbursement
  • Real-world evidence

Teaching Interests

  • Pharmacoeconomics
  • Research Methods
  • Health Care System
  • Biostatistics
  • Drug development and commercialization

Awards, Recognition and Service

  • Graduate Teacher of the Year, College of Pharmacy, Texas A&M University, 2022
  • OptumLabs Health Equity Research Proposal Award (role: Co-PI), 2021
  • Academy of Managed Care Pharmacy International Annual Conference Gold Ribbon Award, 2020
  • OptumLabs Data Warehouse Proposal Award (Role: Co-I), 2019
  • University of California, San Francisco: Biogen Postdoctoral Fellowship in Pharmacoeconomics and Outcomes Research 2011-2013
  • University of California, San Francisco: Urology Best Population Science/Outcome Research Award 2012
  • Duke University Department of Neurobiology Best Student Presentation Award 2009

Representative Publications

  1. Berrios K., Burum A., Jeong E., & Zhong L.* (2022). Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2 Advanced Breast Cancer - a U.S. Payer Perspective Cost-Utility Analysis. Journal of Managed Care & Specialty Pharmacy, in-press.
  2. Ory, M., Lee, S., Dahlke, D. V., Pardo, N., Zhong, L., McCord, C.E., Alonzo, J.P. & Smith, M., L. (2022). Physicians’ Interest in Different Strategies for Supporting Pain Management and Opioid Prescribing: A Cross-Sectional Study. Journal of Opioid Management, in-press.
  3. Ionova L., Vuong W., Sandoval O., Fong J., Vu V., Zhong L., & Wilson L. (2022). Cost-Effectiveness Analysis of Atezolizumab versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA. Clinical Drug Investigation, 42(6), 491-500.
  4. Tran A.T., Rizk E., Haas E.M., Naufal G., Zhong L., & Swan J.T. (2022). Real-World Data on Liposomal Bupivacaine and Inpatient Hospital Costs after Colorectal Surgery. Journal of Surgical Research, 272, 175-183.
  5. Chan A., Dang C., Wisniewski J., Weng X., Hynson E., Zhong L., & Wilson L. (2022). A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology, 45(2), 66-73.
  6. Dong L., Lin S., Zhong L., Nian D., Li Y., Wang R., Zhou W., Weng X., & Xu X. (2022). Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis. Clinical Breast Cancer, 22(1), e21-e29
  7. Chen Y., Wu L., Hernández‐Muñoz J.J., Miller M.J., Pope M., Huyan Y., & Zhong L.* (2022). The Economic Burden of Systemic Sclerosis—A Systematic Review. International Journal of Rheumatic Diseases, 25(2), 110-120.
  8. Li Y., Lin S., Zhong L., Luo S., Huang X., Huang X., Dong L., Xu X., & Weng X. (2021). Is Olaparib Cost-Effective in Metastatic Castration-Resistant Prostate Cancer Patients with at Least One Favorable Gene Mutation in BRCA1, BRCA2 or ATM? Pharmacogenomics, 22(13), 809-819.
  9. Narsipur, N., Bulla, S., Yoo, C., Do, B., Tran, K., Zhong, L., & Wilson, L. (2021). Cost-Effectiveness of Adding Daratumumab or Bortezomib to Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma. Journal of Managed Care & Specialty Pharmacy, 27(12), 1691-1702.
  10. Smith, M. L., Zhong, L., Lee, S., Towne, S. D. Jr., & Ory, M. G. (2021). Effectiveness and Economic Impact of a Diabetes Education Program among Adults with Type 2 Diabetes in South Texas. BMC Public Health, 21(1), 1-12.
  11. Jeong, E., Wang, C., Wilson, L., & Zhong, L.* (2021). Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women. Frontiers in Oncology, 11:658054.
  12. Hernández-Muñoz, J., Chandni, K.R., Zhong, L., Alonzo, A.P. & Sprenger, L. (2021). Impact of a Pharmaceutical Care Incentive Program on the Asthma Medication Ratio among Pediatric Patients with Persistent Asthma Enrolled in a Medicaid Program. Journal of Managed Care & Specialty Pharmacy, 27(6), 714-723.
  13. Le, V., Zhong, L., Narsipur, N., Hays, E., Tran, D. K., Rosario, K. & Wilson, L. (2021). Cost-Effectiveness of Ribociclib + Endocrine Therapy versus Placebo + Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer. Journal of Managed Care & Specialty Pharmacy, 27(3), 327-338.
  14. Lin S., Luo S., Zhong L., Lai S., Zeng D., Rao X., Huang P., & Weng X. (2020). Cost-Effectiveness of Atezolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer. International Journal of Clinical Pharmacy, 42(4), 1175-1183.
  15. Weng X., Luo S., Lin S., Zhong L., Li M., Xin R., Huang P., & Xu X. (2020). Cost‐Utility Analysis of Pembrolizumab versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels. Oncology Research, 28(2), 117-125.
  16. Zhong L.*, Pope M., Shen Y., Hernandez J.J., & Wu L. (2019). Prevalence and Incidence of Systemic Sclerosis: A Systematic Review and Meta‐Analysis. International Journal of Rheumatic Diseases, 22(12), 2096-2107. 
  17. 17.  Tang J., Zhong L., Paoli C., Paciorek A., Carroll P., & Wilson L. (2019). Longitudinal Comparison of Patient-level Outcomes and Costs across Prostate Cancer Treatments with Urinary Problems. American Journal of Men’s Health, 13(2), 1-9.
  18. 18.  Wu L. & Zhong L.* (2019). Budget Impact Analysis of Niraparib and Olaparib for Maintenance Treatment of Platinum-sensitive, Recurrent Ovarian Cancer in the US. Journal of Medical Economics, 22(2), 187-195.
  19. Zhong L.*, Tran A.T., Tomasino T., Nugent E., & Smith J.A. (2018). Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum Sensitive, Recurrent Ovarian Cancer. Journal of Managed Care & Specialty Pharmacy. 24(12), 1219-1228.
  20. Wilson L., Loucks A., Gipson G., Zhong L., Bui C., Miller E., Owen M., Pelletier D., Goodin D., Waubant E., & McCulloch C. (2015). Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies: Development and Results of a Ratings-Based Conjoint Analysis. International Journal of MS Care, 17(2), 74-82.
  21. Wilson L., Loucks A., Bui C., Gipson G., Zhong L., Schwartzburg A., Crabtree E., Goodin D., Waubant E., & McCulloch C. (2014). Patient Centered Decision Making: Use of Conjoint Analysis to Determine Risk Benefit Trade-Offs for Preference-Sensitive Treatment Choices. Journal of the Neurological Sciences. 344(1-2), 80-87.
  22. Wilson L., Tang J., Zhong L., Balani G., Gipson G., Xiang P., Yu D., & Srinivas S. (2014). New Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Can Cost-Effectiveness Analysis Help in Treatment Decisions? Journal of Oncology Pharmacy Practice, 20(6), 417–425.
  23. Zhong L., Pon V., Srinivas S., Nguyen N., Frear M., Kwon S., Gong C,. Malmstrom R., & Wilson L. (2013). Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis. PLoS One, 8(5), e64275.
  24. Schwartz N.U., Zhong L., Bellemer A., & Tracey W.D. (2012). Egg Laying Decision in Drosophila are Consistent with Foraging Costs of Larval Progeny. PLoS One, 7(5), e37910.
  25. Zhong L., Bellemer B., Yan H., Honjo K., Robertson J., Hwang R.Y., Pitt G.S., & Tracey W.D. (2012). Thermosensory and Nonthermosensory Isoforms of Drosophila Melanogaster TRPA1 Reveal Heat-Sensor Domains of a ThermoTRP Channel. Cell Reports, 1(1), 43-55. (¶ authors contributed equally)
  26. Zhong L., Hwang R.Y., & Tracey W.D. (2010). Pickpocket is a DEG/ENaC Protein Required for Mechanical Nociception in Drosophila Larvae. Current Biology, 20(5), 429–434. (¶ authors contributed equally)
  27. Zhong L., Hwang R.Y., Xu Y., Johnson T., Zhang F., Deisseroth K., & Tracey W.D. (2007). Nociceptive Neurons Protect Drosophila Larvae from Parasitoid Wasps. Current Biology, 17(24), 2105-2116. (¶ authors contributed equally)

 

*as Corresponding Author, student authorships are indicated with “____”